Yuhan Corporation (000105.KS)
KRW 101900.0
(-3.04%)
KRW 101900.0
(-3.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 93.5 Billion KRW | 43.03% |
| 2022 | 95.14 Billion KRW | -7.25% |
| 2021 | 102.58 Billion KRW | -46.78% |
| 2020 | 192.76 Billion KRW | 381.83% |
| 2019 | 40 Billion KRW | -30.4% |
| 2018 | 57.48 Billion KRW | -47.28% |
| 2017 | 109.03 Billion KRW | -32.38% |
| 2016 | 161.24 Billion KRW | 27.93% |
| 2015 | 126.04 Billion KRW | 38.59% |
| 2014 | 90.94 Billion KRW | 5.19% |
| 2013 | 86.46 Billion KRW | 7.04% |
| 2012 | 80.77 Billion KRW | -14.27% |
| 2011 | 94.21 Billion KRW | -26.39% |
| 2010 | 128 Billion KRW | 5.15% |
| 2009 | 121.73 Billion KRW | -3.11% |
| 2008 | 125.64 Billion KRW | 36.46% |
| 2007 | 92.07 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 32.06 Billion KRW | 152.24% |
| 2024 Q1 | 12.71 Billion KRW | -86.28% |
| 2023 Q4 | 92.65 Billion KRW | 372.98% |
| 2023 FY | 136.08 Billion KRW | 43.03% |
| 2023 Q1 | 22.23 Billion KRW | -40.86% |
| 2023 Q2 | 8.67 Billion KRW | -60.97% |
| 2023 Q3 | 19.59 Billion KRW | 125.74% |
| 2022 FY | 95.14 Billion KRW | -7.25% |
| 2022 Q2 | 34.07 Billion KRW | 113.87% |
| 2022 Q1 | 15.93 Billion KRW | -6.97% |
| 2022 Q4 | 37.6 Billion KRW | 578.79% |
| 2022 Q3 | 5.53 Billion KRW | -83.74% |
| 2021 Q1 | 20.6 Billion KRW | 62.59% |
| 2021 Q2 | 34.15 Billion KRW | 65.74% |
| 2021 FY | 102.58 Billion KRW | -46.78% |
| 2021 Q3 | 30.69 Billion KRW | -10.13% |
| 2021 Q4 | 17.12 Billion KRW | -44.2% |
| 2020 Q1 | 115.78 Billion KRW | 2394.06% |
| 2020 Q3 | 30.39 Billion KRW | -10.33% |
| 2020 Q4 | 12.67 Billion KRW | -58.31% |
| 2020 FY | 192.76 Billion KRW | 381.83% |
| 2020 Q2 | 33.89 Billion KRW | -70.72% |
| 2019 Q4 | 4.64 Billion KRW | -67.61% |
| 2019 Q2 | 5.46 Billion KRW | -64.93% |
| 2019 Q1 | 15.56 Billion KRW | 75.6% |
| 2019 FY | 40 Billion KRW | -30.4% |
| 2019 Q3 | 14.33 Billion KRW | 162.52% |
| 2018 Q2 | 16.35 Billion KRW | -21.05% |
| 2018 FY | 57.48 Billion KRW | -47.28% |
| 2018 Q4 | 8.86 Billion KRW | -23.19% |
| 2018 Q3 | 11.54 Billion KRW | -29.43% |
| 2018 Q1 | 20.71 Billion KRW | -3.78% |
| 2017 Q4 | 21.53 Billion KRW | -17.08% |
| 2017 FY | 109.03 Billion KRW | -32.38% |
| 2017 Q1 | 29.54 Billion KRW | -42.99% |
| 2017 Q2 | 32.07 Billion KRW | 8.56% |
| 2017 Q3 | 25.96 Billion KRW | -19.03% |
| 2016 Q1 | 51.27 Billion KRW | 100.51% |
| 2016 Q2 | 34.07 Billion KRW | -33.54% |
| 2016 Q3 | 24.07 Billion KRW | -29.35% |
| 2016 FY | 161.24 Billion KRW | 27.93% |
| 2016 Q4 | 51.82 Billion KRW | 115.24% |
| 2015 Q3 | 44.89 Billion KRW | 45.11% |
| 2015 Q4 | 25.57 Billion KRW | -43.05% |
| 2015 FY | 126.04 Billion KRW | 38.59% |
| 2015 Q1 | 24.63 Billion KRW | 39.76% |
| 2015 Q2 | 30.94 Billion KRW | 25.59% |
| 2014 Q1 | 21.62 Billion KRW | -2.2% |
| 2014 FY | 90.94 Billion KRW | 5.19% |
| 2014 Q4 | 17.62 Billion KRW | -29.93% |
| 2014 Q3 | 25.15 Billion KRW | -5.2% |
| 2014 Q2 | 26.53 Billion KRW | 22.69% |
| 2013 Q3 | 17.41 Billion KRW | -25.48% |
| 2013 Q4 | 22.11 Billion KRW | 26.95% |
| 2013 FY | 86.46 Billion KRW | 7.04% |
| 2013 Q1 | 23.55 Billion KRW | 13.87% |
| 2013 Q2 | 23.37 Billion KRW | -0.76% |
| 2012 Q2 | 13.46 Billion KRW | -50.12% |
| 2012 Q1 | 27 Billion KRW | 0.0% |
| 2012 Q3 | 24.33 Billion KRW | 80.71% |
| 2012 Q4 | 20.68 Billion KRW | -15.01% |
| 2012 FY | 80.77 Billion KRW | -14.27% |
| 2011 Q1 | 29.86 Billion KRW | 19.14% |
| 2011 FY | 94.21 Billion KRW | -26.39% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 17.54 Billion KRW | -10.47% |
| 2011 Q2 | 19.59 Billion KRW | -34.38% |
| 2010 Q3 | 28.94 Billion KRW | -22.82% |
| 2010 Q2 | 37.5 Billion KRW | 2.76% |
| 2010 Q1 | 36.49 Billion KRW | 44.56% |
| 2010 Q4 | 25.06 Billion KRW | -13.41% |
| 2010 FY | 128 Billion KRW | 5.15% |
| 2009 Q3 | 29.14 Billion KRW | -4.14% |
| 2009 Q4 | 25.24 Billion KRW | -13.38% |
| 2009 FY | 121.73 Billion KRW | -3.11% |
| 2009 Q1 | 36.52 Billion KRW | 56.23% |
| 2009 Q2 | 30.4 Billion KRW | -16.75% |
| 2008 Q4 | 23.37 Billion KRW | -38.26% |
| 2008 FY | 125.64 Billion KRW | 36.46% |
| 2008 Q1 | 30.6 Billion KRW | 122.24% |
| 2008 Q2 | 33.83 Billion KRW | 10.57% |
| 2008 Q3 | 37.86 Billion KRW | 11.9% |
| 2007 FY | 92.07 Billion KRW | 0.0% |
| 2007 Q1 | 23.02 Billion KRW | 0.0% |
| 2007 Q2 | 30.75 Billion KRW | 33.56% |
| 2007 Q3 | 24.39 Billion KRW | -20.67% |
| 2007 Q4 | 13.77 Billion KRW | -43.57% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 1402.198% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | -61.253% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 256.93% |
| HANDOK Inc. | -28.79 Billion KRW | 424.715% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 1211.2% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -740.727% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 476.872% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 36.054% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -2565.147% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 3830.81% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 4608.855% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 2166.584% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -318.71% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 1402.198% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 546.54% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -2509.54% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 179.065% |
| JW Holdings Corporation | 19.02 Billion KRW | -391.476% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 218.474% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 56.0% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -152.685% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 263.121% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -1427.495% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -5521.121% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -1768.418% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 1402.198% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -152.964% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 16.136% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -152.685% |
| Yuhan Corporation | 93.5 Billion KRW | 0.0% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 675.453% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 2512.812% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -1428.127% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -152.685% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -394.608% |
| Korea United Pharm Inc. | 48.26 Billion KRW | -93.755% |
| CKD Bio Corp. | -24.19 Billion KRW | 486.523% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -290.976% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -240.8% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -214.061% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 263.121% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | -98.925% |
| Boryung Corporation | 40.2 Billion KRW | -132.595% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 398.47% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 3830.81% |
| JW Lifescience Corporation | 28.14 Billion KRW | -232.254% |